- Home
- APH vs JNJ Comparison
APH vs JNJ Comparison
Compare APH & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APH | JNJ |
|---|---|---|
| Founded | 1932 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.0B | 542.4B |
| IPO Year | 1994 | 2003 |
Fundamental Metrics
Financial Performance| Metric | APH | JNJ |
|---|---|---|
| Price | $158.59 | $235.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 20 |
| Target Price | $154.00 | ★ $238.20 |
| AVG Volume (30 Days) | ★ 10.0M | 6.5M |
| Earning Date | 04-29-2026 | 04-14-2026 |
| Dividend Yield | 0.67% | ★ 2.36% |
| EPS Growth | 73.96 | ★ 90.50 |
| EPS | 0.72 | ★ 2.14 |
| Revenue | N/A | N/A |
| Revenue This Year | $37.60 | $6.63 |
| Revenue Next Year | $12.19 | $7.43 |
| P/E Ratio | $213.61 | ★ $112.56 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $92.22 | $149.04 |
| 52 Week High | $167.13 | $251.71 |
Technical Indicators
Market Signals| Indicator | APH | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 65.58 | 57.45 |
| Support Level | $123.24 | $233.83 |
| Resistance Level | $167.13 | $246.40 |
| Average True Range (ATR) | 6.23 | 4.36 |
| MACD | 1.71 | 1.36 |
| Stochastic Oscillator | 95.56 | 74.95 |
Price Performance
Historical ComparisonAbout APH Amphenol Corporation
Amphenol is a global supplier of connectors, sensors, and interconnect systems. It holds the second-largest connector market share globally and sells into the automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks end markets. Amphenol is diversified geographically, with operations in 40 countries.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.